This job has expired

You will need to login before you can apply for a job.

Sr. Scientist/Principal Scientist - Bioinformatics

Acrivon Therapeutics
Watertown, Massachusetts
Start date
Sep 20, 2023

View more

Job Details


Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform enables the creation of drug-specific proprietary OncoSignature® companion diagnostics that are used to identify the patients most likely to benefit from Acrivon’s drug candidates, referred to as patient responders. Acrivon is currently advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial across multiple tumor types, which the AP3 platform predicts will have a high proportion of patient responders based on OncoSignature®-predicted sensitivity to ACR-368. In addition to ACR-368, Acrivon is also developing internally-discovered preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response, or DDR, and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.


Acrivon Therapeutics is seeking a Senior Scientist/Principal Scientist - Bioinformatics to apply computational approaches to analyze and integrate proteomics, phosphoproteomics, systems biology and machine learnings approaches to support our drug discovery and development efforts. The ideal candidate will work closely within a multi-disciplinary team to leverage Acrivon’s unique AP3 platform. Experience in developing data analytical tools and extracting biological insights proteomics and phosphoproteomics will be important. Additionally, hands on experience of leveraging artificial intelligence/machine learning approaches with multi-omics and real-world data will be highly valuable.


Duties and Responsibilities:

  • Contribute to development of computational pipelines for large-scale proteomics and phosphoproteomics data
  • Provide customized computational analysis, working in collaboration with proteomics, biology, and biomarker development teams
  • Develop and maintain interactive web-based applications that integrate both internal and external data within the cloud environment
  • Apply data mining, text mining, machine-learning, and network visualization techniques for biomarker discovery

Qualifications include:

  • Ph.D. or M.S. in Computational biology, Bioinformatics, Engineering or Computer Sciences
  • 3-8 years of demonstrated ability in applying bioinformatics or computational biology approaches in an industry setting, preferably in oncology.
  • Hands on experience with development of computational workflows and data analyses for transcriptomics and/or proteomics data.
  • Strong coding skills required, proficiency in R, Python or other scripting languages, and experience with data processing, statistical analysis, and data visualization
  • Experience implementing workflows to process high throughput -omics data and performing downstream analysis that generates biological insight
  • Experience building web-based applications for end users R Shiny or web development frameworks (e.g. Django/Flask/Streamlit)
  • Excellent communication and presentation skills with demonstrated record of peer-reviewed publication
  • Team player with ability to nurture productive collaborative relationship with internal and external partner


Acrivon is a clinical stage oncology company leveraging our unique precision medicine platform, called Acrivon Predictive Precision Proteomics (AP3), for development of our drug pipeline. AP3 is used to generate proprietary OncoSignature® companion diagnostics to identify the patients who will benefit from our medicines.

The name Acrivon (derived from Greek for “accurate”) embodies how our OncoSignature® tests link the patient’s active tumor-driving mechanisms with the drug’s mode-of-action to accurately match our therapies with patients who will benefit independent of underlying genetic tumor alterations. Our pipeline includes the advanced Phase 2 lead program, ACR-368 (prexasertib), a clinically active CHK1/2 inhibitor, as well as preclinical programs targeting critical nodes in DNA Damage Response (DDR) and cell cycle regulation.

Acrivon’s team is a rare blend of leading scientific pioneers and highly accomplished executives. The team is located at two Centers of Excellence in Boston and Lund/Copenhagen in Scandinavia leveraging regional expertise, infrastructure, and capabilities.

In addition to learning from some of the field’s greatest minds, our committed team members are encouraged to realize their full potential in work and life. We’re a passionate group that values openness, creativity, fresh perspectives, transformative ideas, and a positive can-do attitude. We value diversity, integrity, and passion for scientific excellence, and care deeply about our patients.

If you have the drive and passion to build the future with us, please see our current open positions.

Company info
480 Arsenal Way

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert